This is a multicenter, randomized controlled, open-label study, and the purpose of this study
is to compare the efficiency and safety of PVD regimen (Pomalidomide & Bortezomib &
Dexamethasone) versus VD regimen (Bortezomib & Dexamethasone) in NDMM patients with RI. The
main efficacy indicator is VGPR after 4 cycles of induction therapy.
Phase:
Phase 2
Details
Lead Sponsor:
RenJi Hospital
Collaborators:
Ningbo No. 1 Hospital Peking University People's Hospital Peking University Shenzhen Hospital Shanghai 6th People's Hospital Shanghai Changzheng Hospital The First Affiliated Hospital of Nanchang University The First Affiliated Hospital with Nanjing Medical University The Third People's Hospital of Chengdu Xinhua Hospital, Shanghai Jiao Tong University School of Medicine